Health and Healthcare

AbbVie : ABBV

All AbbVie Articles

587 Articles

Jon C. Ogg | Feb 15, 2018 at 1:20 PM EST

AbbVie Delivers on Promise of Higher Dividend and Stronger Stock Buybacks

AbbVie is joining the companies raising their shareholder rewards. The pharmaceutical products maker has announced how it will further commit…

Chris Lange | Feb 12, 2018 at 9:35 AM EST

Short Sellers Can’t Make Up Their Minds on Major Pharma

The January 31 short interest data have been compared with the previous figures, and short interest moves in these selected…

Lee Jackson | Feb 1, 2018 at 9:40 AM EST

Merrill Lynch Rates 5 Dividend Aristocrat Stocks as Top 2018 Buys

While not the most exciting companies in the world, these five Dividend Aristocrats will certainly hold up much better than…

Lee Jackson | Jan 29, 2018 at 9:15 AM EST

Top Analyst Upgrades and Downgrades: AbbVie, Apple, Exact Sciences, Freeport-McMoran, Laboratory Corp, Splunk and More

The top analyst upgrades, downgrades and other research calls from Monday include AbbVie, Apple, Exact Sciences, Freeport-McMoran, Laboratory Corp and…

Chris Lange | Jan 26, 2018 at 4:08 PM EST

Friday’s Biggest Winners and Losers in the S&P 500

Friday was a positive day for the U.S. markets. We are currently in the midst of the fourth quarter earnings…

Chris Lange | Jan 26, 2018 at 8:50 AM EST

AbbVie’s Q4 Boosted by Strong Segment Results

AbbVie reported better-than-expected fourth-quarter financial results before the markets opened on Friday.

Chris Lange | Jan 25, 2018 at 10:10 AM EST

Major Pharma Short Interest Keeps Climbing

The January 12 short interest data have been compared with the previous figures, and short interest in most of these…

Lee Jackson | Jan 25, 2018 at 10:00 AM EST

SunTrust Bullish on Blue Chip Large-Cap Pharmaceuticals: 4 to Buy Now

With the market trading at very extended valuations, and the S&P 500 on the longest streak ever without a 5%…

Chris Lange | Jan 21, 2018 at 10:20 AM EST

Netflix, Ford and More Big Earnings to Watch For This Week

24/7 Wall St. has put together a preview of Netflix, Ford, AbbVie and other top companies reporting their latest quarterly…

Chris Lange | Jan 11, 2018 at 9:45 AM EST

Major Pharma Short Interest Takes a Plunge

The December 29 short interest data have been compared with the previous figures, and short interest in most of these…

Chris Lange | Jan 6, 2018 at 8:55 AM EST

20 More Biopharma Catalysts Coming in 2018

Credit Suisse has put together a list of biopharma companies in its coverage universe that stand to make significant moves…

Jon C. Ogg | Jan 4, 2018 at 9:20 AM EST

Top Analyst Upgrades and Downgrades: Alphabet, Avon, Bank of America, Intel, Roku, Snap, Western Digital and Many More

The top analyst upgrades, downgrades and other research calls from Thursday include Alphabet, Avon, Bank of America, Intel, Roku, Snap…

Jon C. Ogg | Dec 28, 2017 at 11:20 AM EST

10 Things That Could Wreck the Bull Market in Stocks in 2018

Is it finally time to consider the old adage that "nothing lasts forever" for the bull market as we enter…

Chris Lange | Dec 28, 2017 at 10:25 AM EST

More and More Short Sellers Raising the Stakes in Major Pharma

The December 15 short interest data have been compared with the previous figures, and short interest in these selected pharmaceutical…

Chris Lange | Dec 12, 2017 at 10:40 AM EST

Short Sellers Can’t Make Up Their Minds on Major Pharma

The November 30 short interest data have been compared with the previous figures, and short interest in these selected pharmaceutical…

1 … 21 22 23 24 25 … 40

AbbVie : ABBV

All AbbVie Articles

AbbVie Delivers on Promise of Higher Dividend and Stronger Stock Buybacks

Short Sellers Can’t Make Up Their Minds on Major Pharma

Merrill Lynch Rates 5 Dividend Aristocrat Stocks as Top 2018 Buys

Top Analyst Upgrades and Downgrades: AbbVie, Apple, Exact Sciences, Freeport-McMoran, Laboratory Corp, Splunk and More

Friday’s Biggest Winners and Losers in the S&P 500

AbbVie’s Q4 Boosted by Strong Segment Results

Major Pharma Short Interest Keeps Climbing

SunTrust Bullish on Blue Chip Large-Cap Pharmaceuticals: 4 to Buy Now

Netflix, Ford and More Big Earnings to Watch For This Week

Major Pharma Short Interest Takes a Plunge

20 More Biopharma Catalysts Coming in 2018

Top Analyst Upgrades and Downgrades: Alphabet, Avon, Bank of America, Intel, Roku, Snap, Western Digital and Many More

10 Things That Could Wreck the Bull Market in Stocks in 2018

More and More Short Sellers Raising the Stakes in Major Pharma

Short Sellers Can’t Make Up Their Minds on Major Pharma

SETM Is Up 27% YTD and 150% Over a Year. The S&P 500? Not Even Close.

A 61-Year-Old Widow Claimed Survivor Benefits While Still Working, Then the Earnings Test Triggered a $1-for-$2 Clawback

A Covered Call ETF That Pays 6% Is Beating Vanguard’s Biggest International ETF Right Now

A 61-Year-Old Widow Claimed Survivor Benefits While Still Working, Then the Earnings Test Triggered a $1-for-$2 Clawback

Suze Orman to 54-Year-Old With $600,000: Skip the 1.5% Fee and Manage It Yourself

SETM Is Up 27% YTD and 150% Over a Year. The S&P 500? Not Even Close.

A 61-Year-Old Widow Claimed Survivor Benefits While Still Working, Then the Earnings Test Triggered a $1-for-$2 Clawback

AbbVie : ABBV

All AbbVie Articles

AbbVie Delivers on Promise of Higher Dividend and Stronger Stock Buybacks

Short Sellers Can’t Make Up Their Minds on Major Pharma

Merrill Lynch Rates 5 Dividend Aristocrat Stocks as Top 2018 Buys

Top Analyst Upgrades and Downgrades: AbbVie, Apple, Exact Sciences, Freeport-McMoran, Laboratory Corp, Splunk and More

Friday’s Biggest Winners and Losers in the S&P 500

AbbVie’s Q4 Boosted by Strong Segment Results

Major Pharma Short Interest Keeps Climbing

SunTrust Bullish on Blue Chip Large-Cap Pharmaceuticals: 4 to Buy Now

Netflix, Ford and More Big Earnings to Watch For This Week

Major Pharma Short Interest Takes a Plunge

20 More Biopharma Catalysts Coming in 2018

Top Analyst Upgrades and Downgrades: Alphabet, Avon, Bank of America, Intel, Roku, Snap, Western Digital and Many More

10 Things That Could Wreck the Bull Market in Stocks in 2018

More and More Short Sellers Raising the Stakes in Major Pharma

Short Sellers Can’t Make Up Their Minds on Major Pharma

SETM Is Up 27% YTD and 150% Over a Year. The S&P 500? Not Even Close.

A 61-Year-Old Widow Claimed Survivor Benefits While Still Working, Then the Earnings Test Triggered a $1-for-$2 Clawback

A Covered Call ETF That Pays 6% Is Beating Vanguard’s Biggest International ETF Right Now

Featured Reads

A 61-Year-Old Widow Claimed Survivor Benefits While Still Working, Then the Earnings Test Triggered a $1-for-$2 Clawback

Suze Orman to 54-Year-Old With $600,000: Skip the 1.5% Fee and Manage It Yourself